MA46698A - Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl - Google Patents

Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl

Info

Publication number
MA46698A
MA46698A MA046698A MA46698A MA46698A MA 46698 A MA46698 A MA 46698A MA 046698 A MA046698 A MA 046698A MA 46698 A MA46698 A MA 46698A MA 46698 A MA46698 A MA 46698A
Authority
MA
Morocco
Prior art keywords
têtrahydro
furo
pyridinyl
compounds
Prior art date
Application number
MA046698A
Other languages
English (en)
Inventor
Henricus Jacobus Maria Gijsen
Frederik Jan Rita Rombouts
Brandt Sven Franciscus Anna Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA46698A publication Critical patent/MA46698A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA046698A 2016-11-04 2017-11-03 Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl MA46698A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16197351 2016-11-04
EP17162307 2017-03-22

Publications (1)

Publication Number Publication Date
MA46698A true MA46698A (fr) 2021-04-07

Family

ID=60413151

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046698A MA46698A (fr) 2016-11-04 2017-11-03 Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl

Country Status (10)

Country Link
US (1) US20200062773A1 (fr)
EP (1) EP3535271A1 (fr)
JP (1) JP2019532992A (fr)
KR (1) KR20190075072A (fr)
CN (1) CN109890828A (fr)
AU (1) AU2017353510A1 (fr)
CA (1) CA3039586A1 (fr)
MA (1) MA46698A (fr)
MX (1) MX2019005247A (fr)
WO (1) WO2018083247A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
CA2894919A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Composes de dioxyde d'iminothiazine a condensation oxacyclique en c5, c6 comme inhibiteurs de bace
ES2768823T3 (es) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa
WO2017025565A1 (fr) * 2015-08-12 2017-02-16 H. Lundbeck A/S 2-amino-7a-phényl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines comme inhibiteurs de bace1

Also Published As

Publication number Publication date
AU2017353510A1 (en) 2019-05-02
MX2019005247A (es) 2019-06-24
CA3039586A1 (fr) 2018-05-11
EP3535271A1 (fr) 2019-09-11
KR20190075072A (ko) 2019-06-28
WO2018083247A1 (fr) 2018-05-11
CN109890828A (zh) 2019-06-14
US20200062773A1 (en) 2020-02-27
JP2019532992A (ja) 2019-11-14

Similar Documents

Publication Publication Date Title
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
ZA201903708B (en) New anthelmintic quinoline-3-carboxamide derivatives
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA46188A (fr) Composés indole substitués par pyridyle
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45116A (fr) Composés hétérocycliques comme immunomodulateurs
MA44233A (fr) Nouveaux composés
MA52119A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
IL265752A (en) Spirocyclic compounds
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA42293A (fr) Composés antibactériens
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
IL260011B (en) History of water-soluble 5,3-diphenyldiazole compounds
MA42034A (fr) Composés pipéridiniques tricycliques
MA51221A (fr) Composés de pyrazolopyridinone
MA49885A (fr) Composés macrocycliques
MA49880A (fr) Composés anticancéreux
MA43791A (fr) Composés de carbapénème
MA43799A (fr) Composés de 2-oxindole
DK3515454T3 (da) Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan